208 related articles for article (PubMed ID: 26836515)
21. The effect of Parkinson's disease on the dynamics of on-line and proactive cognitive control during action selection.
Wylie SA; Ridderinkhof KR; Bashore TR; van den Wildenberg WP
J Cogn Neurosci; 2010 Sep; 22(9):2058-73. PubMed ID: 19702465
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of dopaminergic medication on basic motor performance and executive functions in Parkinson's disease.
Michely J; Barbe MT; Hoffstaedter F; Timmermann L; Eickhoff SB; Fink GR; Grefkes C
Neuropsychologia; 2012 Aug; 50(10):2506-14. PubMed ID: 22776611
[TBL] [Abstract][Full Text] [Related]
23. Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset.
Hanna-Pladdy B; Pahwa R; Lyons KE
J Int Neuropsychol Soc; 2015 Apr; 21(4):259-70. PubMed ID: 25923830
[TBL] [Abstract][Full Text] [Related]
24. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
[TBL] [Abstract][Full Text] [Related]
25. Impact of Parkinson's disease and dopaminergic medication on adaptation to explicit and implicit visuomotor perturbations.
Mongeon D; Blanchet P; Messier J
Brain Cogn; 2013 Mar; 81(2):271-82. PubMed ID: 23313834
[TBL] [Abstract][Full Text] [Related]
26. Don't look now or look away: two sources of saccadic disinhibition in Parkinson's disease?
van Stockum S; MacAskill M; Anderson T; Dalrymple-Alford J
Neuropsychologia; 2008 Nov; 46(13):3108-15. PubMed ID: 18674551
[TBL] [Abstract][Full Text] [Related]
27. Dopaminergic medication shifts the balance between going and stopping in Parkinson's disease.
Wylie SA; van Wouwe NC; Godfrey SG; Bissett PG; Logan GD; Kanoff KE; Claassen DO; Neimat JS; van den Wildenberg WPM
Neuropsychologia; 2018 Jan; 109():262-269. PubMed ID: 29269306
[TBL] [Abstract][Full Text] [Related]
28. Intact action segmentation in Parkinson's disease: Hypothesis testing using a novel computational approach.
Schiffer AM; Nevado-Holgado AJ; Johnen A; Schönberger AR; Fink GR; Schubotz RI
Neuropsychologia; 2015 Nov; 78():29-40. PubMed ID: 26432343
[TBL] [Abstract][Full Text] [Related]
29. Dopaminergic modulation of novelty repetition in Parkinson's disease: A study of P3 event-related brain potentials.
Bertram M; Warren CV; Lange F; Seer C; Steinke A; Wegner F; Schrader C; Dressler D; Dengler R; Kopp B
Clin Neurophysiol; 2020 Dec; 131(12):2841-2850. PubMed ID: 33137574
[TBL] [Abstract][Full Text] [Related]
30. Dopaminergic medication boosts action-effect binding in Parkinson's disease.
Moore JW; Schneider SA; Schwingenschuh P; Moretto G; Bhatia KP; Haggard P
Neuropsychologia; 2010 Mar; 48(4):1125-32. PubMed ID: 20018200
[TBL] [Abstract][Full Text] [Related]
31. Advance preparation of set-switches in Parkinson's disease.
Pollux PM
Neuropsychologia; 2004; 42(7):912-9. PubMed ID: 14998705
[TBL] [Abstract][Full Text] [Related]
32. Stroop test performance in impulsive and non impulsive patients with Parkinson's disease.
Djamshidian A; O'Sullivan SS; Lees A; Averbeck BB
Parkinsonism Relat Disord; 2011 Mar; 17(3):212-4. PubMed ID: 21247790
[TBL] [Abstract][Full Text] [Related]
33. Impulsive oculomotor action selection in Parkinson's disease.
Duprez J; Houvenaghel JF; Argaud S; Naudet F; Robert G; Drapier D; Vérin M; Sauleau P
Neuropsychologia; 2017 Jan; 95():250-258. PubMed ID: 28039058
[TBL] [Abstract][Full Text] [Related]
34. Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors.
Claassen DO; van den Wildenberg WP; Harrison MB; van Wouwe NC; Kanoff K; Neimat JS; Wylie SA
Pharmacol Biochem Behav; 2015 Feb; 129():19-25. PubMed ID: 25459105
[TBL] [Abstract][Full Text] [Related]
35. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
[TBL] [Abstract][Full Text] [Related]
36. [Dopamine dysregulation syndrome in Parkinson's disease and restless legs syndrome].
Bayard S; Cochen De Cock V; Dauvillers Y
Geriatr Psychol Neuropsychiatr Vieil; 2011 Jun; 9(2):227-35. PubMed ID: 21690031
[TBL] [Abstract][Full Text] [Related]
37. How attentional boost interacts with reward: the effect of dopaminergic medications in Parkinson's disease.
Kéri S; Nagy H; Levy-Gigi E; Kelemen O
Eur J Neurosci; 2013 Dec; 38(11):3650-8. PubMed ID: 24011183
[TBL] [Abstract][Full Text] [Related]
38. Self-reported rates of impulsivity in Parkinson's Disease.
Aumann MA; Stark AJ; Hughes SB; Lin YC; Kang H; Bradley E; Zald DH; Claassen DO
Ann Clin Transl Neurol; 2020 Apr; 7(4):437-448. PubMed ID: 32227451
[TBL] [Abstract][Full Text] [Related]
39. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
Tomer R; Aharon-Peretz J; Tsitrinbaum Z
Neuropsychologia; 2007 Jan; 45(2):357-67. PubMed ID: 16876208
[TBL] [Abstract][Full Text] [Related]
40. Impact of Parkinson's disease on proprioceptively based on-line movement control.
Mongeon D; Blanchet P; Bergeron S; Messier J
Exp Brain Res; 2015 Sep; 233(9):2707-21. PubMed ID: 26055990
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
